A Pilot Study of Exenatide Actions in Alzheimer's Disease.

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D

Current Alzheimer research1 Jan 2019Cited by 135 (Europe PMC)

PMID31518224PMCIDPMC7476877DOI10.2174/1567205016666190913155950PepBankPUB-31518224

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialSafety outcome
In early Alzheimer's disease, exenatide was safe and well tolerated.
In plain wordsIn early Alzheimer's disease, exenatide was safe and well tolerated.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTolerability
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was safe and well-tolerated, showing an expectedly higher incidence of nausea and decreased appetite compared to placebo and decreasing glucose and GLP-1 during Oral Glucose Tolerance Tests.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822401
02HumanRandomized controlled trialSafety outcome
In early Alzheimer's disease, exenatide increased nausea compared with placebo.
In plain wordsIn early Alzheimer's disease, exenatide increased nausea compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was safe and well-tolerated, showing an expectedly higher incidence of nausea and decreased appetite compared to placebo and decreasing glucose and GLP-1 during Oral Glucose Tolerance Tests.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822402
03HumanRandomized controlled trialSafety outcome
In early Alzheimer's disease, decreased appetite was more frequent with exenatide than placebo.
In plain wordsIn early Alzheimer's disease, decreased appetite was more frequent with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDecreased appetite
Study
n: not reported in source
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was safe and well-tolerated, showing an expectedly higher incidence of nausea and decreased appetite compared to placebo and decreasing glucose and GLP-1 during Oral Glucose Tolerance Tests.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822403
04HumanRandomized controlled trialEfficacy outcome
In early Alzheimer's disease, exenatide decreased glucose during oral glucose tolerance tests.
In plain wordsIn early Alzheimer's disease, exenatide decreased glucose during glucose tolerance tests.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose during oral glucose tolerance tests
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was safe and well-tolerated, showing an expectedly higher incidence of nausea and decreased appetite compared to placebo and decreasing glucose and GLP-1 during Oral Glucose Tolerance Tests.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822404
05HumanRandomized controlled trialMechanism
In early Alzheimer's disease, exenatide decreased GLP-1 during oral glucose tolerance tests.
In plain wordsIn early Alzheimer's disease, exenatide decreased GLP-1 during glucose tolerance tests.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGLP-1 during oral glucose tolerance tests
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide was safe and well-tolerated, showing an expectedly higher incidence of nausea and decreased appetite compared to placebo and decreasing glucose and GLP-1 during Oral Glucose Tolerance Tests.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822405
06HumanRandomized controlled trialEfficacy outcome
In early Alzheimer's disease, clinical, cognitive, MRI and fluid biomarker measures showed no differences or trends versus placebo, except extracellular-vesicle Aβ42.
In plain wordsIn early Alzheimer's disease, clinical, cognitive, MRI and fluid measures showed no differences versus placebo, except extracellular-vesicle Aβ42.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeClinical and cognitive measures and MRI and fluid biomarkers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide treatment produced no differences or trends compared to placebo for clinical and cognitive measures, MRI cortical thickness and volume, or biomarkers in CSF, plasma, and plasma neuronal extracellular vesicles (EV) except for a reduction of Aβ42 in EVs.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822406
07HumanRandomized controlled trialMechanism
In early Alzheimer's disease, exenatide reduced neuronal extracellular-vesicle Aβ42 versus placebo.
In plain wordsIn early Alzheimer's disease, exenatide reduced neuronal extracellular-vesicle Aβ42 versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAβ42 in neuronal extracellular vesicles
Study
n: not reported in source
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
Exenatide treatment produced no differences or trends compared to placebo for clinical and cognitive measures, MRI cortical thickness and volume, or biomarkers in CSF, plasma, and plasma neuronal extracellular vesicles (EV) except for a reduction of Aβ42 in EVs.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.
Report a problemFND-3151822407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2Results postedNCT01255163

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

National Institute on Aging (NIA)n = 5721 Nov 2010 to 18 Nov 2016

Alzheimer's Disease · Mild Cognitive Impairment

Trial page ClinicalTrials.govUpdated 22 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.